Tidepath

Growth-hormone peptides

Tesamorelin

Also called Egrifta

Raises growth hormone, and has a current FDA label.

Status
Approved by the FDA, as Egrifta.
How it's taken
By injection
Where doses come from
Doses on the label
Half-life
About 8-11 minutes

What it is

Tesamorelin is a more stable version of GHRH, the brain signal that prompts growth-hormone release. It's FDA-approved as Egrifta to reduce excess belly fat in adults with HIV who have lipodystrophy, a change in where the body stores fat.

What makes it distinct

It has a current label, a half-life (the time it takes for half a dose to clear) measured in people: 8 minutes for Egrifta SV and 11 for Egrifta WR, in healthy volunteers, and fixed doses on the label rather than a community range. What it's approved for is narrow, and its label says it isn't for weight loss.

Doses on the label

1.28–1.4 mg isn't a range to pick from. It spans two fixed product doses that can't be swapped for each other: Egrifta WR at 1.28 mg a day and Egrifta SV at 1.4 mg a day. Amounts in between aren't label doses. A 2 mg entry matches the dose of an older, discontinued version of the product, and it's more than either current label dose, so Tidepath asks you to confirm it.

Source FDA labels for Egrifta WR and Egrifta SV. Checked 29 Oct 2026.

This describes the source. It isn't advice.

Open questions

  • What it does outside its approved use. The trials on its label that tested how well it works were in adults with HIV and lipodystrophy.

More in Growth-hormone peptides